ClinicalTrials.gg
RecruitingNCT07227584Updated Aug 17, 2026

ALL Backbone in AYAs

A Phase 2 interventional study of Blinatumomab and Oncaspar in Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia and Acute Lymphoblastic Leukemia (ALL), sponsored by Dana-Farber Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years to 51 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Non-randomized
Ages
18 Years to 51 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing vincristine in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 6 open to participants now, 11 under way, 3 of them phase 3. Vincristine · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
26th of 59
67 · median 55
Started
2026
with 1 other
Phase 2
27 of 59
4 open now
Primary completion
2030-07
later than 8 of 10 live
Registered
58th of 59
by date

Among the 59 studies testing vincristine in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 26th largest by planned enrollment, is one of 2 that started in 2026, is one of 27 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 58th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

6 of the 59 studies testing vincristine in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About vincristine

Vincristine: first FDA approval 1963 (ONCOVIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 51 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing vincristine in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs).

The names of the study drugs involved in this study are:

  • blinatumomab (a type of immunotherapy drug)
  • cyclophosphamide (a type of chemotherapy drug)
  • cytarabine (a type of antineoplastic agent)
  • dexamethasone (a type of synthetic glucocorticoid)
  • doxorubicin (a type of antineoplastic agent)
  • etoposide (a type of antineoplastic agent)
  • mercaptopurine (a type of antineoplastic agent)
  • methotrexate (a type of chemotherapy drug)
  • pegaspargase (a type of antineoplastic agent)
  • vincristine (a type of antineoplastic agent)
Read the detailed description

This Phase 2, single-arm research study is to evaluate a chemotherapy regiment the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs).

The U.S. Food and Drug Administration (FDA) has approved all of the drugs of treatment being studied but the investigators of this research study want to understand more about the safety and effectiveness of the chemotherapy regimen in adolescents and young adults with newly diagnosed Philadelphia chromosome-negative ALL.

The research study procedures include screening for eligibility, in-clinic visits, blood tests, urine tests, saliva tests, X-rays, electrocardiograms (ECGs), echocardiograms (ECHOs), Dual-Energy X-ray Absorptiometry (DEXA) scans, bone marrow aspirations/biopsies.

Participation in this study is expected to last about 10 years, 2 years of treatment followed by 8 years of follow up.

It is expected that about 67 people will take part in this research study.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Philadelphia Chromosome-Negative Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia (ALL)
  • Leukemia

Keywords

  • Acute Lymphoblastic Leukemia
  • Philadelphia Chromosome-Negative lymphoblastic leukemia
  • Acute Lymphoblastic Leukemia (ALL)
  • Leukemia
04

Who can participate

Ages eligible
18 Years to 51 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

3.1.1Confirmed diagnosis of Philadelphia chromosome-negative acute lymphoblastic leukemia.

  • Diagnosis should be made by peripheral blood, bone marrow aspirate, bone marrow , or tissue biopsy demonstrating ≥25% involvement by lymphoblasts, with flow cytometry or immunohistochemistry confirming B-ALL or T-ALL.

    o Participants with B-cell and T-cell lymphoblastic lymphoma are eligible regardless of bone marrow involvement Participants with mixed phenotype acute leukemia (MPAL) ARE eligible, if an ALL regimen is felt to be most appropriate treatment.

  • Participants with CNS leukemia ARE eligible. 3.1.2 Allowed prior therapy:
  • , hydroxyurea, all-trans retinoic acid (ATRA).
  • IT chemotherapy.
  • Emergent radiation therapy or leukapheresis for life threatening complications.
  • One cycle of prior chemotherapy (i.e. an induction cycle given at another institution and participant transfers care for post-induction treatment; OR a participant does not meet eligibility prior to induction but does meet eligibility after remission induction).

3.1.3 Age 18.00 - 50.99 years 3.1.4 Direct \<1.4 mg/dL (total bilirubin \< 1.4 mg/dL is acceptable). 3.1.5 Willingness to use effective means of . The effects of chemotherapy on the developing human fetus are unknown. For this reason and because therapeutic agents used in this trial are known to be teratogenic, women of and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study.

3.1.6 Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

Philadelphia chromosome-positive / BCR::ABL1 fusion 3.2.2 Participants with mature B-cell (Burkitt's) ALL. Mature B-cell ALL is defined by the presence of surface immunoglobulin AND any of the following: t(8;14)(q24;q32), t(8;22), t(2;8), or c-myc-gene rearrangement by FISH, PCR or other testing. [FISH/PCR testing for c-myc rearrangements is not required prior to study entry, but it is suggested for participants with surface immunoglobulin expression or L3 morphology]. 3.2.3 Participants with acute undifferentiated leukemia. 3.2.4 Participants receiving any other agent for this condition.

3.2.5 Uncontrolled intercurrent illness including but not limited to ongoing infection with vital sign instability (hypotension, respiratory insufficiency), life-threatening acute tumor lysis syndrome (e.g., with renal failure), symptomatic congestive heart failure, cardiac arrhythmia, intracranial or other uncontrolled bleeding. Circumstances that may significantly interfere with a participant's ability to safely comply with study procedures, such as attend scheduled study visits, adhere to treatment protocols, or complete study assessments. These include a lack of reliable transportation, unstable housing, or psychiatric illness, but reasonable attempts should be made to overcome these circumstances, including but not limited to identifying sponsor, institutional, or thirdparty financial or social support as well as psychiatric consultation for objective assessment. 3.2.6 Sexually active participants of who have not agreed to use an effective method for the duration of study participation are ineligible.

3.2.7 Pregnant women are excluded from this study because many of the agents used on this protocol have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these chemotherapy agents, breastfeeding should be discontinued if the mother is enrolled.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (estimated)

Study arms

  • Experimental
    ALL Backbone Regimen for B-Cell

    * Steroid Prophase (3-dy cycle): Dexamethasone \& cytarabine * Induction IA (29-dy cycle): Vincristine, dexamethasone, pegaspargase, doxorubicin, IT chemotherapy * Induction IB (42-dy cycle): Cyclophosphamide, cytarabine, mercaptopurine, IT chemotherapy * Blinatumomab Cycle 1, 2 (42-dy cycles): Blinatumomab, dexamethasone, IT chemotherapy * Consolidation I: * Phase IA (28-dy cycle), Phase IC (21-dy cycle): Vincristine, mercaptopurine, methotrexate, dexamethasone, cytarabine, etoposide, pegaspargase, IT chemotherapy * Blinatumomab Cycle 3 (42-dy cycle): Dexamethasone, Blinatumomab, IT chemotherapy * Consolidation II (21-dy cycles for 30 wks): Vincristine, dexamethasone, mercaptopurine, doxorubicin, methotrexate, pegaspargase, IT chemotherapy * Blinatumomab Cycle 4 (42-dy cycle): Dexamethasone, Blinatumomab, IT chemotherapy * Continuation (21-dy cycles): Vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy * End of treatment visit * Follow up

    Drug: Blinatumomab · Drug: Oncaspar · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Dexamethasone · Drug: Doxorubicin Hydrochloride · Drug: Etoposide · Drug: Mercaptopurine · Drug: Methotrexate

  • Experimental
    ALL Backbone Regimen for T-Cell

    * Steroid Prophase (3-day cycle): Dexamethasone and cytarabine * Induction IA (29-day cycle): Vincristine, dexamethasone, pegaspargase, doxorubicin, IT chemotherapy * Induction IB (42-day cycle): Cyclophosphamide, cytarabine, mercaptopurine, IT chemotherapy * Consolidation I: * Phase IA (28-day cycle) and Phase IC (21-day cycle): Vincristine, mercaptopurine, methotrexate, dexamethasone, cytarabine, etoposide, pegaspargase, IT chemotherapy * CNS Phase (21-day cycle): Dexamethasone, vincristine, mercaptopurine, pegaspargase, IT chemotherapy * Consolidation II (21-day cycles for 30 weeks): Vincristine, dexamethasone, mercaptopurine, doxorubicin, methotrexate, pegaspargase, IT chemotherapy * Continuation (21-day cycles): Vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy * End of treatment visit * Follow up

    Drug: Blinatumomab · Drug: Oncaspar · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Dexamethasone · Drug: Doxorubicin Hydrochloride · Drug: Etoposide · Drug: Mercaptopurine · Drug: Methotrexate · Drug: Vincristine

Interventions

  • A bispecific T-cell engager (BiTE) antibody, single-use vial via intravenous infusion, per standard of care

    Also known as: Blincyto, NSC# 765986

  • A modified enzyme L-asparaginase, single-use vial via intravenous infusion, per standard of care

    Also known as: PEGASPARGASE, NSC #624239)

  • An alkylating agent, single-use vial via intravenous infusion, per standard of care

    Also known as: Cytoxan, NSC #26271

  • An antineoplastic antimetabolite, multi-dose vial via intrathecal injection (through the spinal space), per standard of care

    Also known as: Cytosine Arabinoside, Ara-C, Cytostar, NSC#63878

  • A synthetic glucocorticoid, tablets or single-use vials via orally or intravenous infusion (through the vein), per standard of care

    Also known as: Decadron, Hexadrol, Dexone, Dexameth, NSC#34521

  • An anthracycline antibiotic, single-use or multi-dose vials via intravenous infusion, per standard of care

    Also known as: Adriamycin, NSC#123127

  • A derivative of podophyllotoxin, multi-dose vial via intravenous infusion, per standard of care

    Also known as: VePesid, Etopophos, VP-16, NSC#141540

  • A purine antagonist, tablet via orally, per standard of care

    Also known as: 6-MP, Purinethol, 6-Mercaptopurine, Purixan, NSC#000755

  • A folate analogue, multi-dose and single-use vials via intrathecal injection, per standard of care

    Also known as: MTX, Amethopterin, Trexall, NSC#000740

  • A vinca alkaloid, single-use vials via intravenous injection, per standard of care

    Also known as: Oncovin, VCR, LCR, NSC#67574

06

What researchers measure

Primary outcomes

  1. Treatment Completion Rate Through Time Point 3 (TP3)

    Treatment completion rate through TP3 is defined as the proportion of Adolescents and Young Adults (AYAs) participants who receive all protocol-specified therapy through TP3, without early discontinuation.

    Time frame: Timeframe for TP3 depends on disease immunophenotype. Participants with CD19-positive B-ALL, TP3 occurs at the end of Blinatumomab Cycle 2 on Day 28 (130 days from study start). For participants with T-cell ALL or those who do not receive blinatum

Secondary outcomes

  1. Rate of Treatment-Related Mortality (TRM)

    Rate of TRM is defined as the proportion of participants who die due to treatment-related causes.

    Time frame: Up to 115 weeks

  2. Rate of Treatment Discontinuation due to Toxicity or Disease

    Rate of treatment discontinuation during Induction, Consolidation, and Continuation phases, defined as the proportion of participants who stop protocol-specified therapy due to regimen-related toxicity and/or treatment failure.

    Time frame: Up to 115 weeks

  3. Rate of Asparaginase Non-Completion

    Rate of asparaginase non-completion is defined as the proportion of participants who did not complete all planned doses of asparaginase per protocol.

    Time frame: This endpoint is assessed during Consolidation II, which occurs approximately from Day 270 to Day 480 of study treatment.

  4. Reason of Asparaginase Non-Completion

    This outcome summarizes the reasons participants discontinue asparaginase treatment earlier than planned.

    Time frame: Up to 115 weeks

  5. Grade 3 Infections Toxicity Rate

    Grade 3 infection toxicity rate is defined as the proportion of participants who experience grade 3 bacterial or fungal infections that are assessed as possibly, probably, or definitely related to the study treatment during the induction, consolidation, and continuation phases. Toxicity grades are determined according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

    Time frame: Adverse events will be followed for 30 days after completion of protocol treatment, with the overall treatment period up to 115 weeks.

  6. Grade 3 Asparaginase-associated Toxicities Rate

    Grade 3 asparaginase-associated toxicity rate is defined as the proportion of participants who experience grade 3 asparaginase-associated toxicities (including thromboembolic events, pancreatitis, hypertriglyceridemia, hyperbilirubinemia, hypersensitivity, and hyperglycemia) that are assessed as possibly, probably, or definitely related to the study treatment during the induction, consolidation, or continuation phases. Toxicity grades are determined according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

    Time frame: Adverse events will be followed for 30 days after completion of protocol treatment, with the overall treatment period up to 115 weeks.

  7. Grade 3 Orthopedic Toxicity Rate

    Grade 3 orthopedic toxicity rate is defined as the proportion of participants who experience grade 3 osteopenia or osteoporosis that are assessed as possibly, probably, or definitely related to the study treatment at the end of treatment, or osteonecrosis (ON) or fractures during or after treatment. Toxicity grades are assigned according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

    Time frame: Adverse events will be followed for 30 days after completion of protocol treatment, with the overall treatment period up to 115 weeks. Ostenonecrosis and fractures will be followed up to 10 years.

  8. Complete remission Rate (CRR)

    CRR is defined as proportion of participants who achieve CR. Complete response (CR) is defined as an interpretable bone marrow with less than 5% malignant lymphoblasts, no lymphoblasts in peripheral blood, an absolute phagocyte count greater than 1000/µL and platelets above 100,000/µL (for participants with M2 marrow at Day 32 who achieve CR at TP2, APC above 500/µL and platelets above 50,000/µL are acceptable), no evidence of extramedullary leukemia or blasts in spinal fluid, at least a 70% reduction in the anterior mediastinal mass if present at diagnosis as measured by the sum of the products of the two greatest diameters on CT or chest X-ray, and for any other large radiographic masses at diagnosis, a 70% reduction in SPD if restaging imaging is obtained.

    Time frame: CR can be documented either at the end of Induction IA (32 days) or Induction IB (74 days).

  9. Measurable Residual Disease (MRD) Negativity Rate at the end of Induction IA (Time Point 1)

    The proportion of who achieve measurable residual disease (MRD) negativity at the end of Induction IA (Time Point 1). MRD negativity is assessed by multiparameter flow cytometry (MPFC), next-generation sequencing (NGS), and/or KMT2A::AFF4 RT-PCR.

    Time frame: At the end of Induction IA (32 days from study start)

  10. Measurable Residual Disease (MRD) Negativity Rate at the end of Induction IB (Time Point 2)

    The proportion of who achieve measurable residual disease (MRD) negativity at the end of Induction IB (Time Point 2). MRD negativity is assessed by multiparameter flow cytometry (MPFC), next-generation sequencing (NGS), and/or KMT2A::AFF4 RT-PCR.

    Time frame: At the end of Induction IB (74 days from study start)

  11. Measurable Residual Disease (MRD) Negativity Rate at Time Point 3 (TP3)

    The proportion of who achieve measurable residual disease (MRD) negativity at TP3. MRD negativity is assessed by multiparameter flow cytometry (MPFC), next-generation sequencing (NGS), and/or KMT2A::AFF4 RT-PCR.

    Time frame: For CD19-positive B-ALL, TP3 is reached at the end of Blinatumomab Cycle 2 on Day 28 (Day 130 from study start). For T-cell ALL or participants not receiving blinatumomab, TP3 occurs on Day 28 of Consolidation IC (Day 102 from study start).

  12. Median Event-Free Survival (EFS)

    EFS based on Kaplan-Meier method is defined as the time from registration to induction failure, relapse, second malignancy, or death due to any cause. Relapse is defined as the presence of more than 5% lymphoblasts in bone marrow confirmed by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests; the development of biopsy-proven extramedullary disease (e.g., CSF, testicle, lymph node, skin); or CNS relapse, defined as a CSF sample with more than 5 WBCs per high-power field with lymphoblasts on cytospin, or two consecutive CSF specimens meeting the CNS-2 criteria (\<5 WBC/µL with lymphoblasts) obtained at least three weeks apart. Participants alive without disease relapse are censored at date of last disease evaluation (which can include clinical evaluation and blood counts, does not require a bone marrow examination).

    Time frame: Up to 10 years

  13. Median Disease-Free Survival (DFS)

    DFS based on Kaplan-Meier method is defined as the time from confirmed complete remission (CR) to the earlier of relapse or death due to any cause. Relapse is defined as the presence of more than 5% lymphoblasts in bone marrow confirmed by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests; the development of biopsy-proven extramedullary disease (e.g., CSF, testicle, lymph node, skin); or CNS relapse, defined as a CSF sample with more than 5 WBCs per high-power field with lymphoblasts on cytospin, or two consecutive CSF specimens meeting the CNS-2 criteria (\<5 WBC/µL with lymphoblasts) obtained at least three weeks apart. Participants who are alive without disease relapse are censored at the date of last disease evaluation.

    Time frame: Up to 10 years

  14. Median Overall Survival (OS)

    Overall Survival (OS) based on Kaplan-Meier method is defined as the time from registration to death due to any cause or censored at date last known alive.

    Time frame: Up to 10 years

  15. Rate of Allogeneic Transplantation

    Rate of allogeneic transplantation is defined as the proportion of participants who undergo allogeneic transplantation while in their first complete remission (CR).

    Time frame: CR can be documented either at the end of Induction IA (32 days) or Induction IB (74 days).

  16. Reason of Allogeneic Transplantation

    This outcome measures the number of participants who undergo allogeneic transplantation in their first complete remission (CR) and the reasons for transplantation.

    Time frame: CR can be documented either at the end of Induction IA (32 days) or Induction IB (74 days).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2030, 51 months after the start.

Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 120. This study's planned 51 months is below that.

Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2025
First posted
Nov 12, 2025
StartActual
Apr 3, 2026
Primary completionEst.
Jul 31, 2030
CompletionEst.
Jul 31, 2035
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07227584
Responsible party
Marlise Luskin, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Nov 12, 2025
Start date
Apr 3, 2026
Primary completion
Jul 31, 2030 (estimated)
Completion
Jul 31, 2035 (estimated)
Last update
Aug 17, 2026

Study contacts

Marlise R Luskin, MD, MSCE
Contact
marlise_luskin@dfci.harvard.edu
617-632-1906
Marlise R Luskin, MD, MSCE
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vincristine

Start the discussion